Clinical Trials in Nashville

Showing 15681-15700 of 20,298 trials

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

NCT01404650

This is a multicenter, non-randomized, single agent, Phase II study of AUY922 in patients with refractory Gastrointestinal Stromal Tumor (GIST). The primary endpoint of this study is to determine progression-free survival (PFS) for patients with GIST receiving AUY922 intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle with restaging at 6 and 12 weeks and then every 9 weeks thereafter. Patients may continue treatment until evidence of disease progression.

Gastrointestinal Stromal Tumor

SCRI Development Innovations, LLC25 participantsStarted Dec 2011

New Haven, Connecticut, United States • Fort Myers, Florida, United States • Orlando, Florida, United States +5 more locations

COMPLETED< 1 mile

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

NCT01070836

The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV) (antibody negative) is lower than in participants who have detectable antibodies to JCV (antibody positive). The secondary objectives of this study are to: Estimate the incidence of PML in natalizumab-treated participants who are anti-JCV antibody negative and anti-JCV antibody positive, based on a meta-analysis of data obtained from this study and other data sources; Define the prevalence of anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving natalizumab within the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program; Determine changes in anti-JCV antibody status over time.

Relapsing Multiple Sclerosis

Biogen35,895 participantsStarted Mar 2010

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Cullman, Alabama, United States +475 more locations

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

Find Trials by Condition in Nashville

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Flurbiprofen Tape for Treatment of Chronic Low Back Pain

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

JC-Virus (JCV) Antibody Program

Study of Tolerant Kidney Transplant Recipients

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

CryoValve SG Pulmonary Human Heart Valve Post Clearance Study

An Observational Study of Childhood Food Allergy

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement

Detecting EGFR T790M Mutations From Circulating Tumor Cells

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)